24/7 Market News Snapshot 24 June, 2025 – iBio, Inc. Common Stock (NASDAQ:IBIO)

June 24, 2025

DENVER, Colo., 24 June, 2025 (www.247marketnews.com) – (NASDAQ:IBIO) are discussed in this article.
iBio, Inc. (NYSE:IBIO) is witnessing a significant positive movement in its stock, with a remarkable increase of over 50% in premarket trading, reaching $1.070 from the previous close of $0.712. The heightened investor interest is evident, with a trading volume surpassing 23 million shares. This surge in stock performance coincides with promising developments from the company, notably in the realm of obesity treatment, where iBio has announced encouraging preclinical results for its engineered amylin receptor agonist antibody.

In a rigorous study utilizing a mouse model of obesity, the antibody demonstrated a remarkable 60% reduction in acute food intake, closely paralleling results from a leading dual amylin and calcitonin receptor agonist peptide, which achieved a 67% reduction. This success marks another milestone in iBio’s strategic collaboration with AstralBio, underscoring the company’s dedication to pioneering innovative therapies.

Dr. Martin Brenner, CEO and Chief Scientific Officer of iBio, emphasized that these findings showcase the potential effectiveness of selective amylin receptor activation, potentially rivaling existing treatment options while enhancing patient tolerability. The amylin receptor, known for its role in regulating satiety and delaying gastric emptying, offers a compelling target for developing therapies aimed at combating obesity and associated cardiometabolic conditions.

iBio’s advanced computational biology and proprietary drug discovery platform are positioned to deliver a pipeline of promising antibody treatments that address the growing obesity epidemic. The company remains committed to revolutionizing therapeutic solutions, promising to meet the urgent demand for effective and well-tolerated obesity treatments. As part of its ongoing engagement with stakeholders, iBio will host a conference call today to discuss these preclinical findings and its obesity pipeline further, positioning itself as a leader in the biopharmaceutical sector.

Related news for (IBIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.